Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index.
Journal
Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
14
08
2019
accepted:
15
10
2019
pubmed:
22
10
2019
medline:
21
7
2020
entrez:
22
10
2019
Statut:
ppublish
Résumé
The Systemic Lupus International Collaborating Clinics (SLICC) frailty index (FI) has been shown to predict mortality, but its association with other important outcomes is unknown. We examined the association of baseline SLICC FI values with damage accrual in the SLICC inception cohort. The baseline visit was defined as the first visit at which both organ damage (SLICC/American College of Rheumatology Damage Index [SDI]) and health-related quality of life (Short Form 36) were assessed. Baseline SLICC FI scores were calculated. Damage accrual was measured by the increase in SDI between the baseline assessment and the last study visit. Multivariable negative binomial regression was used to estimate the association between baseline SLICC FI values and the rate of increase in the SDI during follow-up, adjusting for relevant demographic and clinical characteristics. The 1,549 systemic lupus erythematosus (SLE) patients eligible for this analysis were mostly female (88.7%) with a mean ± SD age of 35.7 ± 13.3 years and a median disease duration of 1.2 years (interquartile range 0.9-1.5 years) at baseline. The mean ± SD baseline SLICC FI was 0.17 ± 0.08. Over a mean ± SD follow-up of 7.2 ± 3.7 years, 653 patients (42.2%) had an increase in SDI. Higher baseline SLICC FI values (per 0.05 increase) were associated with higher rates of increase in the SDI during follow-up (incidence rate ratio [IRR] 1.19 [95% confidence interval 1.13-1.25]), after adjusting for age, sex, ethnicity/region, education, baseline SLE Disease Activity Index 2000, baseline SDI, and baseline use of glucocorticoids, antimalarials, and immunosuppressive agents. Our findings indicate that the SLICC FI predicts damage accrual in incident SLE, which further supports the SLICC FI as a valid health measure in SLE.
Identifiants
pubmed: 31631584
doi: 10.1002/art.41144
pmc: PMC7113092
mid: NIHMS1055504
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
658-666Subventions
Organisme : NCRR NIH HHS
ID : M01 RR000046
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000150
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR025741
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States
Organisme : CIHR
ID : MOP-88526
Pays : Canada
Organisme : NIAMS NIH HHS
ID : P30 AR072579
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR043727
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR069572
Pays : United States
Organisme : NIAMS NIH HHS
ID : P60 AR064464
Pays : United States
Organisme : NIAMS NIH HHS
ID : K24 AR068406
Pays : United States
Organisme : NIAMS NIH HHS
ID : P60 AR048098
Pays : United States
Organisme : NIAMS NIH HHS
ID : K24 AR002138
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
© 2019, American College of Rheumatology.
Références
Rheumatology (Oxford). 2004 Feb;43(2):202-5
pubmed: 12923289
Cancer. 2015 May 15;121(10):1540-7
pubmed: 25529481
J Am Geriatr Soc. 2006 Jun;54(6):975-9
pubmed: 16776795
CMAJ. 2005 Aug 30;173(5):489-95
pubmed: 16129869
Arthritis Rheum. 1999 Apr;42(4):599-608
pubmed: 10211873
Scand J Rheumatol. 2009 Mar-Apr;38(2):121-7
pubmed: 18991189
J Gerontol A Biol Sci Med Sci. 2007 Jul;62(7):738-43
pubmed: 17634321
Arthritis Rheumatol. 2019 Aug;71(8):1297-1307
pubmed: 30771242
J Rheumatol. 2003 Sep;30(9):1955-9
pubmed: 12966597
J Infect Dis. 2014 Oct 15;210(8):1170-9
pubmed: 24903667
Lupus. 2008 Nov;17(11):1042-8
pubmed: 18852231
BMC Geriatr. 2008 Sep 30;8:24
pubmed: 18826625
Biogerontology. 2010 Oct;11(5):547-63
pubmed: 20559726
Lancet. 2013 Mar 2;381(9868):752-62
pubmed: 23395245
Arthritis Rheum. 2008 Mar;58(3):843-53
pubmed: 18311802
J Nutr Health Aging. 2012 Oct;16(10):903-7
pubmed: 23208030
AIDS. 2015 Aug 24;29(13):1633-41
pubmed: 26372273
J Rheumatol. 2014 Apr;41(4):698-705
pubmed: 24584923
CMAJ. 2011 May 17;183(8):E487-94
pubmed: 21540166
Blood. 2018 Feb 1;131(5):515-524
pubmed: 29141942
Interdiscip Top Gerontol. 2015;40:85-98
pubmed: 25341515
Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):455-68
pubmed: 21831027
Interdiscip Top Gerontol Geriatr. 2015;41:66-73
pubmed: 26301980
Semin Arthritis Rheum. 2013 Dec;43(3):352-61
pubmed: 23786872
Arthritis Rheum. 1997 May;40(5):809-13
pubmed: 9153540
BMC Musculoskelet Disord. 2015 Aug 12;16:188
pubmed: 26264937
Lupus. 2001;10(2):93-6
pubmed: 11237132
Arthritis Rheum. 1996 Mar;39(3):363-9
pubmed: 8607884
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
J Rheumatol. 2020 Jan;47(1):72-81
pubmed: 30988130
J Rheumatol. 2002 Jul;29(7):1398-400
pubmed: 12136895
J Rheumatol. 2002 Feb;29(2):288-91
pubmed: 11838846
Ann Rheum Dis. 2015 Sep;74(9):1706-13
pubmed: 24834926
Exp Gerontol. 2018 Jul 1;107:126-129
pubmed: 28847723
Age Ageing. 2012 Mar;41(2):142-7
pubmed: 22345294
J Am Geriatr Soc. 2005 Dec;53(12):2184-9
pubmed: 16398907
Lupus. 2015 Oct;24(12):1248-56
pubmed: 25957301
Arthritis Rheum. 2007 Jan;56(1):265-73
pubmed: 17195230
Lupus. 2019 Sep;28(10):1261-1272
pubmed: 31296137